Updates are available Correction dated 2026-03-03
Click to view Correction: https://doi.org/10.1038/s41551-026-01641-7
-
Authors
Herron, Jeffrey https://orcid.org/0000-0002-9813-0094
Kullmann, Aura https://orcid.org/0000-0001-6625-2946
Denison, Timothy
Goodman, Wayne K.
Gunduz, Aysegul
Neumann, Wolf-Julian https://orcid.org/0000-0002-6758-9708
Provenza, Nicole R. https://orcid.org/0000-0002-6952-5417
Shanechi, Maryam M. https://orcid.org/0000-0002-0544-7720
Sheth, Sameer A.
Starr, Philip A. https://orcid.org/0000-0003-2733-4003
Widge, Alik S. https://orcid.org/0000-0001-8510-341X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH123634)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (UH3NS100548)
- License Information
-
More Information
Article History
Received: 25 September 2023
Accepted: 31 October 2024
First Online: 27 December 2024
Change Date: 3 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41551-026-01641-7
Competing interests
: J.H., A.G., W.K.G., S.A.S., P.A.S. and A.S.W. have received device donations and other in-kind research support from multiple companies that manufacture clinical neurostimulators and/or recording electrodes. A.K. is an employee of NeuroOne, which manufactures neural recording electrodes. T.D. and J.H. were formerly employed by Medtronic, which provided technical support for much of the research discussed. A.S.W., W.K.G., S.A.S. and P.A.S. have received consulting income from companies that manufacture clinical neurostimulators (time spent on DSMB for Neuralink inc. and educational support for fellowship from Medtronic and Boston Scientific). W.K.G. receives royalty payments from Nview, LLC and OCDscales, LLC. S.A.S. has equity in Motif Neuroscience, a company developing adaptive neurostimulation. S.A.S. is a consultant for Zimmer Biomet, Boston Scientific, Neuropace, Koh Young, Varian Medical and Sensoria Therapeutics, and has received consultant fees or research support from Abbott Laboratories. W.-J.N. received honoraria for consulting from InBrain Neuroelectronics (that is, a neurotechnology company) and honoraria for talks from Medtronic (that is, a manufacturer of DBS devices unrelated to this manuscript). M.M.S. is an inventor on University of Southern California’s patents or patent applications related to decoding and closed-loop control approaches (US patent nos. US12097029B1, US20210361244A1 and US20220301688A1), and is a consultant for Paradromics Inc. All authors hold intellectual property in the general area of adaptive neurostimulation.
